ClinicalTrials.gg
CompletedNCT04820452Updated Nov 18, 2024

A Study of IBI302 in Patients With nAMD

A Phase 2 interventional study of Low dose IBI302 and High dose IBI302 in Neovascular Age-related Macular Degeneration, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Completed at 1 site in China. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2024-11-18.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
231
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 106 studies in Macular Degeneration with a site in China — 36 open to participants now, 43 under way, 9 of them phase 3. Macular Degeneration · China.

Enrollment
23rd of 91
231 · median 62
Started
2021
with 7 others
Phase 2
14 of 106
4 open now
Registered
45th of 106
by date
Lead sponsor
7 of 106
Innovent Biologics (Suzhou) Co. Ltd.

Among the 106 studies in Macular Degeneration with a site in China, this one is the 23rd largest by enrollment of the 91 interventional ones that give a count, is one of 8 that started in 2021, is one of 14 in phase 2, and was the 45th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

36 of the 106 studies in Macular Degeneration with a site in China are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Macular Degeneration with a site in China, or all of them as a file.
02

Study summary

This is a multi-center, randomized, double-blind, active-controlled study to evaluate the efficacy and safety of IBI302 in subjects with neovascular age-related macular degeneration.

03

Conditions studied

  • Neovascular Age-related Macular Degeneration
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patient ≥ 50 yrs. of age.
  2. Active subfoveal or parafoveal CNV secondary to neovascular AMD.
  3. BCVA score of 24-73 letters using ETDRS charts in the study eye.
  4. Willing and able to sign form and comply with visit and study procedures per protocol.

Exclusion criteria

Exclusion criteria

  1. Concomitant diseases that may cause subjects fail to respond to the treatment or confuse the interpretation of the study results;
  2. Presence of uncontrolled glaucoma in the study eye (defined as IOP≥25mmHg despite the standardized treatment);
  3. Presence of active intraocular or periocular inflammation or infection;
  4. Prior any treatment of following in the study eye:

    1. Anti-VEGF therapy or anti-complement therapy within 3 months prior to screening;
    2. Laser photocoagulation within 3 months prior to screening;
    3. Photodynamic therapy or vitreoretinal surgery;
    4. Intraocular injection within 6 months prior to enrollment;
  5. Presence of any systemic disease: including but not limited toactive infections (such as active viral hepatitis); unstable angina; cerebrovascular accident or transient cerebral ischemia (within 6 months prior to selection); myocardial infarction (within 6 months prior to selection); serious arrhythmia requiring medical treatment; liver, kidney or metabolic diseases; or malignant tumor;
  6. History of severe /allergy to active ingredients or any of the study drug, or fluorescein and povidone iodine;
  7. Pregnant or lactating women or women preparing to become pregnant or breastfeeding during the study period;
  8. Participated in any clinical study of any other drug within three months prior to enrollment, or attempted to participate in other drug trials during the study;
  9. Other conditions unsuitable for enrollment judged by investigators
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
231 participants (actual)

Study arms

  • Experimental
    cohort 1 IBI302 treated with high dose level of IBI302

    Drug: IBI302 4mg/eye;Intraocular injection

    Biological: High dose IBI302

  • Active comparator
    Aflibercept

    Drug: Aflibercept 2mg/eye;Intraocular injection

    Drug: Aflibercept

  • Experimental
    cohort 1 IBI302 treated with low dose level of IBI302

    Drug: IBI302 2mg/eye;Intraocular injection

    Biological: Low dose IBI302

Interventions

  • BiologicalLow dose IBI302

    Low dose IBI302 intravitreal injection given as every other month after three loading monthly injection

  • High dose IBI302 intravitreal injection given as every other month after three loading monthly injection

  • Intraocular injection

06

What researchers measure

Primary outcomes

  1. The visual efficacy of IBI302

    Time frame: Baseline to week 36

Secondary outcomes

  1. other visual effects of IBI302

    the proportion if BCVA improvement ≥0,5,10 or 15 letters at week 12, 28, 36 and 52.

    Time frame: Baseline to week 52

  2. the anatomical effects of IBI302 on OCT

    the mean change of central subfield thickness from BL to week 52 at week 12, 28, 36 and 52

    Time frame: Baseline to week 52

  3. the anatomical effects of IBI302 on FFA

    the change of CNV area, CNV leakage area, total lesion area from BL to week 36 or 52

    Time frame: Baseline to week 52

  4. the safety of IBI302

    the incidence of ocular AE or any systemic AE, TEAE, SAE

    Time frame: Baseline to week 52

  5. Immunogenicity of IBI302

    the positive rate of anti-drug antibody and neutralizing antibody

    Time frame: Baseline to week 52

07

Study locations

1 site
  • Innovent Biologics (Suzhou) Co,Ltd.
    Suzhou, Jiangsu 215123, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Jan 2023, 20 months.

Of 66 industry-sponsored phase 2 interventional studies under Macular Degeneration, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 20 months is close to that.

Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 16 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2021
First posted
Mar 29, 2021
StartActual
Apr 28, 2021
Primary completionActual
Jan 13, 2023
CompletionActual
Jan 13, 2023
Last update
Nov 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04820452
Responsible party
Sponsor
First posted
Mar 29, 2021
Start date
Apr 28, 2021
Primary completion
Jan 13, 2023
Completion
Jan 13, 2023
Last update
Nov 18, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IBI302

Start the discussion